Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.

Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.

<h4>Background</h4>Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as t...

Full description

Bibliographic Details
Main Authors: Winnie Chua, Jonathan P Law, Victor R Cardoso, Yanish Purmah, Georgiana Neculau, Muhammad Jawad-Ul-Qamar, Kalisha Russell, Ashley Turner, Samantha P Tull, Frantisek Nehaj, Paul Brady, Peter Kastner, André Ziegler, Georgios V Gkoutos, Davor Pavlovic, Charles J Ferro, Paulus Kirchhof, Larissa Fabritz
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-02-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1003405

Internet

https://doi.org/10.1371/journal.pmed.1003405

Similar Items